

**HEAD OF CEF UNIT**

Parma, 23<sup>rd</sup> June 2010  
Ref. AF/ef (2010) – out 4945615 –

Dr. Hratche Koundarjian  
Breast Cancer UK  
BM Box 7767  
London WC1N 3XX  
United Kingdom

**Re:** Your letter to Pr. Dr. Klaus-Dieter Jany dated 23<sup>rd</sup> June 2010

Dear Dr. Koundarjian,

In reply to your letter to Pr. Dr. Klaus Dieter Jany, and having discussed the issue together, we would like to thank you and the undersigned scientists and organisations for your interest in EFSA's work. We are happy to see that you agree with us on the need for high quality science to be used in risk assessment.

As you know, the members of EFSA's scientific Panels have been selected through open competition on the basis of their scientific excellence and independence. They have a leading role in science and in scientific risk assessment in their Member States or in international organisations. They are highly committed and devoted to contributing to EFSA's missions, providing high quality and independent scientific advice to help risk managers in the EU to protect public health.

Concerning the current literature review on bisphenol A (BPA), a number of leading external experts were appointed to the relevant Working Groups, where they have pooled their specific knowledge and experience with that of the CEF Panel members. As in EFSA's previous opinions on BPA, hundreds of scientific papers are being considered, including those which you cite in your letter.

As you correctly mention, study design is of major importance and I wish to emphasise that careful attention is paid to this aspect in all of EFSA's work.

During this evaluation process, EFSA has also exchanged views on BPA with scientists from organisations in charge of risk assessment in the area of public health in Europe and worldwide.

The opinion on BPA is due to be adopted on 8 July and should be published a few days later.

If you have any further question, do not hesitate to contact me.

Yours sincerely,



Alexandre Feigenbaum